Clovis Oncology

Realizing the promise of personalized medicines for cancer

Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company achieved FDA approval for Rubraca (rucaparib) in 2016 to treat women with advanced ovarian cancer whose tumors have a BRCA mutation. Clovis completed its IPO in 2011.

Status
IPO in 2011 (NASDAQ: CLVS)
Year of Investment
2009
Strategy
Life Sciences
Location
Boulder, Colorado
Social Media